Nvidia-OpenAI Deal, AT&T Bonds, and Biotech M&A

In a busy morning for market movers, Bloomberg's Stock Movers Report, hosted by Karen Moscow and featuring Bloomberg's Dan Curtis, delved into several key developments impacting major companies. The discussion highlighted potential financing for OpenAI, a significant biotech acquisition, a bond offering from AT&T, and earnings news from AstraZeneca.

Nvidia and OpenAI's Ambitious Data Center Plans

The report detailed that Nvidia (NASDAQ:NVDA) is reportedly in discussions to provide a substantial $250 billion backstop for OpenAI. This guarantee is intended to help secure financing for a massive 10-gigawatt data center project being developed by SoftBank in southern Ohio. According to the Wall Street Journal, this backing would assist OpenAI in raising debt at a lower rate, crucial for an unprofitable company without an investment-grade rating. This move signifies a growing trend of larger, creditworthy companies supporting AI ventures. The sheer scale of the project is staggering, with the total cost estimated to exceed $500 billion, potentially becoming the largest project announced to date. For perspective, 10 gigawatts is equivalent to the electricity consumption of New York City during peak summer demand. This news contributed to a 1% rise in Nvidia's shares in pre-market trading, with the broader AI trade also showing strength, including gains for SK Hynix and SanDisk.

Argenics Acquires Forte Biosciences

In the biotech sector, Forte Biosciences (NASDAQ:FBRX) is set to be acquired by Argenics for approximately $2.2 billion in cash. Forte Biosciences, an immunology company, is developing promising drug candidates for vitiligo and celiac disease, with potential applications for multiple autoimmune conditions. This acquisition aligns with Argenics' strategy to broaden its immunology portfolio, which has previously relied heavily on a single blockbuster drug. The boards of directors for both companies have approved the transaction, which is expected to close this quarter. The pre-market trading saw Forte's stock trading just below the acquisition price of $77 per share.

The full discussion can be found on Bloomberg Podcast's YouTube channel.

AstraZeneca's Strong Earnings and Pipeline

Turning to pharmaceutical news, AstraZeneca (NASDAQ:AZN) reported higher-than-expected profits, largely driven by its successful cancer medicines. The company's American Depositary Receipts (ADRs) saw a 1.5% increase in pre-market trading. AstraZeneca has been focusing on next-generation cancer treatments, with key drugs exceeding revenue estimates. The company also announced promising results for an experimental gastric cancer treatment, though it also faced a setback with a rare blood disorder treatment. AstraZeneca is actively working to bolster its cardiovascular portfolio, including an experimental obesity pill. The company reiterated its full-year outlook, suggesting continued confidence in its growth trajectory.

AT&T's Bond Offering Amidst Positive Momentum

Telecommunications giant AT&T (NYSE:T) is reportedly issuing Euro and Sterling bonds worth at least $2.2 billion. This move comes as the company aims to refinance debt. The offering is notable as it launches during a typically quiet period for the European bond market. AT&T last raised funds in the publicly syndicated market over a year ago, although it did access U.S. markets for $6 billion in April. This strategic move follows a strong performance for AT&T, with its stock surging 10% last week, marking its second-best week since 2022, fueled by strong second-quarter earnings that showed robust mobile subscriber additions. The company is looking to capitalize on this positive momentum to make its bond offering more impactful.

Trip.com Faces Regulatory Scrutiny

Finally, the report touched upon Trip.com (NASDAQ:TCOM), the Chinese online travel agent. The company has received an order from government regulators to halt certain antitrust operations, refund hotel operators, and pay a fine exceeding half a billion dollars. Despite the significant penalty, which Goldman Sachs noted as historically high, Trip.com's ADRs were up 4% in pre-market trading. This resilience is attributed to the fact that the company had already ceased the flagged practices in January and that the fine is expected to be well-covered by its liquid holdings.